Skip to main content

Table 1 The baseline characteristics of the study participants enrolled during the therapeutic efficacy study in Uganda 2018–2019

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Characteristics, location Treatment arm
AL (N = 305) DP (N = 285)
Female sex n/N (%)
 Kwania district 59/104 (56.7) 54/95 (56.8)
 Busia district 63/102 (61.8) 48/94 (51.1)
 Arua district 48/99 (48.5) 56/96 (58.3)
Age in years, median (range)
 Kwania district 6.0 (1.0–10.0) 6.0 (1.0–10.0)
 Busia district 2.0 (0.5–10.0) 3.0 (0.5–10.0)
 Arua district 3.0 (0.5–10.0) 3.0 (0.8–10.0)
Temperature, °C, mean (SD)
 Kwania district 37.4 (1.3) 37.4 (1.2)
 Busia district 38.0 (0.9) 37.8 (0.9)
 Arua district 38.4 (1.0) 38.1 (1.0)
Parasite density/μl, Geometric mean, (95% CI)
 Kwania district 36,910 (29,193–46,666) 30,906 (24,067–39,687)
 Busia district 35,073 (28,235–43,567) 29,142 (22,643–37,506)
 Arua district 43,536 (34,973–54,194) 45,083 (35,329–57,530)
Hemoglobin level, g/dl, mean (SD)
 Kwania district 11.4 (1.4) 11.4 (1.5)
 Busia district 11.5 (1.7) 11.7 (1.9)
 Arua district 11.1 (1.7) 11.4 (1.6)
  1. AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; SD, standard deviation; CI, confidence interval